Oxford Biodynamics
OBD · AIM · Health Care · mcap £16m · 0.1p 2 open situations →
Open · 2
Funding requirement by late August
Led to New CEO commercial refocus – MKCG sales force deal signed; seven reps deploying
The company said on 30 June 2026 that it needed new funds by late August, with cash of £1.38m at 31 May and no non-dilutive deal. It announced a £9.15m placing on 10 August; shareholders approved it on 26 August and the shares were admitted on 27 August. Only Vulpes' £250,000 balance is outstanding, now due by 30 October.
- Size
- £9.15m placing of 9,150,000,000 new shares
- Price
- £0.001 per Placing Share
- Admission
- Placing Shares admitted to AIM on 27 August 2026 after approval at the 26 August meeting
- Outstanding
- £250,000 of Vulpes' £500,000 commitment is unpaid
- Next milestone
- Payment deadline extended to 30 October 2026
- Related party
- Director Martin Diggle co-founded Vulpes; independent directors consider the extension fair and reasonable
Next: Vulpes to pay outstanding £250,000 placing balance · 30 Oct 2026
- 1 Oct 2026 Placing completed; £250,000 still outstanding
- 30 Jun 2026 Funding route under discussion
New CEO commercial refocus
Follows from Funding requirement by late August – Placing completed; £250,000 still outstanding
Next: commercial progress update in scheduled financial reporting
- 30 Jun 2026 MKCG sales force deal signed; seven reps deploying
- 30 Jun 2026 CEO appointed; commercial push under way
- 30 Jun 2026 CEO in post; board seat pending
Closed · 1
Company filings. Not investment advice.